Does Removing the Appendix Reduce Future Colorectal Cancer Risk?

After appendectomy:

Appendix → histopathological examination → incidental neoplasm may be detected

With antibiotic treatment:

Appendix remains in situ → no immediate tissue diagnosis

This creates a fundamental difference in diagnostic opportunity.

The CODA investigators also highlighted the possibility of missed appendiceal neoplasms when the appendix is not removed.

What Does the Existing Evidence Show?

The relationship between appendectomy and colorectal cancer is far from settled.

Does Removing the Appendix Reduce Future Colorectal Cancer Risk?

Systematic Review and Meta-analysis

A 2023 systematic review and meta-analysis examined 22 studies from three continents after screening 1,743 articles.

Overall, previous appendectomy was associated with:

OR 1.31 (95% CI 1.05–1.62) for colorectal cancer.

In other words, this meta-analysis did not demonstrate a protective effect of appendectomy.

Interestingly, results varied substantially by geographical population, sex and tumour location, highlighting the heterogeneity of the available evidence.

What does this mean?

The 2026 finding of lower colorectal-cancer risk after appendectomy is therefore not consistent with all previous observational evidence.

This is precisely why a single retrospective database study should not be interpreted as establishing causality.

What Do Randomized Trials Tell Us?

The major randomized trials of appendectomy versus antibiotics were designed primarily to answer another question:

Can selected patients with acute uncomplicat ndomized Controlled Trial

The CODA trial, (Comparison of Outcomes of antibiotic Drugs and Appendectomy) published in the New England Journal of Medicine, randomized 1,552 adults with imaging-confirmed appendicitis to antibiotics or appendectomy.

Antibiotics were non-inferior to appendectomy for 30-day health status.

However:

• 29% of patients receiving antibiotics had undergone appendectomy by 90 days.
• The rate was 41% in patients with an appendicolith.
• It was 25% in patients without an appendicolith.
• Complications were more frequent with antibiotics overall, largely because of the appendicolith subgroup.

Important: CODA does not demonstrate either an increased or decreased long-term colorectal-cancer risk from antibiotic management.

Read the CODA randomized trial in NEJM

APPAC Trial: What Happens 10 Years After Antibiotic Treatment?

The APPAC trial provides some of the longest randomized evidence available.

The original trial enrolled 530 adults aged 18–60 years with CT-confirmed uncomplicated appendicitis.

At 10-year follow-up:

• True appendicitis recurrence: 37.8%
• Cumulative appendectomy rate: 44.3%
• 10-year complication rate:
  • Initial appendectomy group: 27.4%
  • Initial antibiotic group: 8.5%
• Quality of life was not significantly different between groups.

The investigators concluded that antibiotics remain an option for appropriately selected adults with uncomplicated appendicitis.

Importantly, the APPAC study also found that the long-term risk of malignancy associated with uncomplicated acute appendicitis was low, reported as approximately 1.2% in the trial population.

Read the 10-year APPAC follow-up in JAMA

A Crucial Distinction: Appendicitis vs Colorectal Cancer

The current evidence supports separating two different questions.

Question 1

Does appendectomy prevent future colorectal cancer?

Currently unproven.

Question 2

Can acute appendicitis sometimes be an early manifestation of an occult colorectal malignancy?

Yes, this possibility is supported by observational evidence and is clinically important.

Therefore, the clinically relevant issue may not simply be:

“Should the appendix be removed to prevent cancer?”

Instead, it may be:

“Which patients presenting with appendicitis require additional evaluation for occult colorectal or appendiceal pathology?”

Which Patients Deserve Particular Attention?

Although the optimal surveillance strategy remains uncertain and should be individualized, clinicians should consider the possibility of underlying colorectal pathology particularly in patients with:

• Older age at presentation
• Atypical appendicitis
• Recurrent appendicitis
• Persistent symptoms after treatment
• Unexplained weight loss
• Iron-deficiency anaemia
• Rectal bleeding
• Change in bowel habits
• Caecal or right-sided colonic abnormalities on imaging
• Appendiceal or caecal mass
• Suspicious appendiceal thickening
• Family history of colorectal cancer
• Other established colorectal-cancer risk factors

The 2026 investigators specifically highlight age, family history and genetic predisposition as potentially relevant factors when considering patient selection and follow-up.

What Should Gastro Surgeons and Gastroenterologists Take From This?

The new study should not be interpreted as:

“Appendectomy is necessary to prevent colorectal cancer.”

Instead, it raises a more nuanced hypothesis:

Could leaving the appendix in place after non-operative treatment of appendicitis be associated with a different long-term colorectal-cancer risk?

This question remains unanswered.

At present, the evidence consists of:

2026 observational signal

previous conflicting observational studies

systematic-review evidence showing heterogeneous associations

RCT evidence supporting antibiotics as an option for selected uncomplicated appendicitis

Therefore, there is insufficient evidence to use colorectal-cancer prevention as an independent indication for appendectomy.

The Evidence in One Table

What We Still Need to Know

Does Removing the Appendix Reduce Future Colorectal Cancer Risk?

The key unanswered question is:

Does non-operative management of acute appendicitis itself alter long-term colorectal-cancer risk, or are observed differences explained by confounding, cancer-related appendiceal obstruction, surveillance differences, or other factors?

The ideal study would be a large prospective cohort or long-term randomized comparison with:

• Standardized colorectal-cancer surveillance
• Long-term follow-up
• Detailed CT findings
• Age-stratified analysis
• Appendicolith status
• Family history
• Genetic risk
• Colonoscopy data
• Histopathology
• Appendiceal neoplasia
• Right-sided versus left-sided colorectal cancer
• Cancer stage at diagnosis

Until such evidence is available, the 2026 study should be viewed as an important signal requiring validation, rather than definitive evidence that appendectomy prevents colorectal cancer.

Conclusion

Does Removing the Appendix Reduce Future Colorectal Cancer Risk?

The relationship between acute appendicitis, appendectomy, antibiotics and colorectal cancer is more complex than the headline “appendectomy reduces cancer risk by 58%” suggests.

The newly reported 2026 TriNetX study found a substantial association between appendectomy and a lower subsequent colorectal-cancer diagnosis rate. However, it is a retrospective observational study and has not yet undergone peer review.

Existing evidence is inconsistent. A 2023 systematic review and meta-analysis actually found an overall association between appendectomy and increased colorectal-cancer risk, while large randomized trials demonstrate that antibiotics can be an appropriate option for selected patients with uncomplicated appendicitis.

The most important clinical message is therefore not that every patient with appendicitis should undergo appendectomy to prevent cancer.

Rather:

Appendicitis can occasionally be associated with underlying colorectal or appendiceal pathology, and long-term oncological considerations may deserve attention when selecting patients for non-operative management and planning follow-up.

Further prospective research is needed before any colorectal-cancer-prevention effect of appendectomy can be established.

References & Further Reading

1. Akula M, et al. Risk of Colorectal Cancer Following Appendectomy.
Scientific Forum, American College of Surgeons Clinical Congress 2026.
American College of Surgeons – study report

2. Salminen P, et al. Antibiotic Therapy for Uncomplicated Acute Appendicitis: Ten-Year Follow-Up of the APPAC Randomized Clinical Trial. JAMA. 2026;335:1041–1049. DOI: 10.1001/jama.2025.25921.
JAMA – full article

3. CODA Collaborative. A Randomized Trial Comparing Antibiotics with Appendectomy for Appendicitis. N Engl J Med. 2020;383:1907–1919. DOI: 10.1056/NEJMoa2014320.
NEJM – full article

4. Liu Z, Ma X, Zhu C, Fang J-Y. Risk of colorectal cancer after appendectomy: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2023;38:350–358. DOI: 10.1111/jgh.16108.
PubMed